Pre-Test Taking a Closer Look at S1P Receptor Modulators in Ulcerative Colitis: Practical Considerations and Optimal Positioning Pre-Test Sphingosine-1 receptor (S1PR) modulators mitigate ulcerative colitis (UC) pathogenesis through which mechanism? Accumulation of inflammatory cytokines in the GI system Dysregulated Th1 immune response Pathological changes in the gut microbiome Reducing circulating lymphocyte counts Unsure Data from the TRUE NORTH study demonstrated that 37% of patients treated with ______ maintained clinical remission. Amiselimod Etrasimod Fingolimod Ozanimod Unsure Based on current data, S1PR modulators are potentially best positioned for: First-line induction therapy for biologic naïve patients Maintenance therapy for biologic-experienced patients Induction and maintenance for UC mesalamine failures Induction therapy with an eventual switch to biologic agent for maintenance Unsure How confident are you in your ability to appropriately utilize S1PR modulators and manage/mitigate AEs in clinical practice? Very confident Confident Somewhat confident Not very confident Not at all confident How confident are you in your ability to manage/mitigate potential AEs associated with S1PR modulators in clinical practice? Very confident Confident Somewhat confident Not very confident Not at all confident
